HCW Biologics Inc

Company Profile

HCW Biologics Inc had its IPO on 2021-07-20 under the ticker symbol HCWB.

The company operates in the Healthcare sector and Biotechnology industry. HCW Biologics Inc has a staff strength of 44 employees.

Stock update

Shares of HCW Biologics Inc opened at $2.01 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.96 - $2.1, and closed at $2.03.

This is a +3.05% increase from the previous day's closing price.

A total volume of 16,882 shares were traded at the close of the day’s session.

In the last one week, shares of HCW Biologics Inc have increased by +16%.

HCW Biologics Inc's Key Ratios

HCW Biologics Inc has a market cap of $62.87 million, indicating a price to book ratio of 1.728 and a price to sales ratio of 13.3337.

In the last 12-months HCW Biologics Inc’s revenue was $3.82 million with a gross profit of $4.10 million and an EBITDA of $-18549312. The EBITDA ratio measures HCW Biologics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, HCW Biologics Inc’s operating margin was -512.63% while its return on assets stood at -28.14% with a return of equity of -50.05%.

In Q2, HCW Biologics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 37.2%.

HCW Biologics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.51 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into HCW Biologics Inc’s profitability.

HCW Biologics Inc stock is trading at a EV to sales ratio of 9.9916 and a EV to EBITDA ratio of -4.4951. Its price to sales ratio in the trailing 12-months stood at 13.3337.

HCW Biologics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$39.48 million

Total Liabilities

$4.54 million

Operating Cash Flow

$0

Capital Expenditure

$1.56 million

Dividend Payout Ratio

0%

HCW Biologics Inc ended 2025 with $39.48 million in total assets and $0 in total liabilities. Its intangible assets were valued at $39.48 million while shareholder equity stood at $28.59 million.

HCW Biologics Inc ended 2025 with $0 in deferred long-term liabilities, $4.54 million in other current liabilities, 3593.00 in common stock, $-54913152.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.45 million and cash and short-term investments were $17.41 million. The company’s total short-term debt was $0 while long-term debt stood at $6.36 million.

HCW Biologics Inc’s total current assets stands at $19.80 million while long-term investments were $1.60 million and short-term investments were $9.96 million. Its net receivables were $707211.00 compared to accounts payable of $2.12 million and inventory worth $1.36 million.

In 2025, HCW Biologics Inc's operating cash flow was $0 while its capital expenditure stood at $1.56 million.

Comparatively, HCW Biologics Inc paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$2.03

52-Week High

$2.79

52-Week Low

$1.08

Analyst Target Price

$7

HCW Biologics Inc stock is currently trading at $2.03 per share. It touched a 52-week high of $2.79 and a 52-week low of $2.79. Analysts tracking the stock have a 12-month average target price of $7.

Its 50-day moving average was $2.07 and 200-day moving average was $1.86 The short ratio stood at 2.99 indicating a short percent outstanding of 0%.

Around 5047.1% of the company’s stock are held by insiders while 244.7% are held by institutions.